SCHEMBL3620581

SCHEMBL3620581

Clc1cccc(Cl)c1-c1nnc2cc(I)ccn12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
ALDH1A1 P00352 2/20 0.47
GRM2 Q14416 1/20 0.42
TSHR P16473 1/20 0.36
KDM4E B2RXH2 3/20 0.36
KMT2A Q03164 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HTT P42858 2/20 0.35
MAPK1 P28482 1/20 0.35
CSNK1A1 P48729 2/20 0.35
CLK4 Q9HAZ1 2/20 0.35
DYRK1B Q9Y463 2/20 0.35
ABL1 P00519 1/20 0.35
PDGFRA P16234 1/20 0.35
CDK7 P50613 1/20 0.35
BTK Q06187 1/20 0.35
MAP4K2 Q12851 1/20 0.35
AURKB Q96GD4 1/20 0.35
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3623290 0.83 HSD11B1 (0.47) LMNASMN1; SMN2ALDH1A1KDM4EKMT2A
SCHEMBL3622123 0.81 MAPK14 (0.43) LMNASMN1; SMN2ALDH1A1GRM2KDM4E
SCHEMBL3620228 0.76 ABL1 (0.51) LMNASMN1; SMN2ALDH1A1TSHRKDM4E
SCHEMBL3614156 0.74 MAPK13 (0.48) LMNASMN1; SMN2ALDH1A1KDM4EKMT2A
SCHEMBL3622223 0.71 DNMT1 (0.33) DNMT1
SCHEMBL3621998 0.71 HSD11B1 (0.40) KDM4EMAPK13PDE2APDE10AHSD11B1
SCHEMBL3619423 0.70 TNKS (0.38) KDM4EKMT2AHSD17B10CSNK1A1CLK4
SCHEMBL3619896 0.67 DNMT1 (0.30) DNMT1
SCHEMBL379822 0.67 HSD11B1 (0.50) LMNASMN1; SMN2ALDH1A1KDM4EKMT2A
SCHEMBL15013681 0.67 SMN1; SMN2 (0.51) LMNASMN1; SMN2ALDH1A1GRM2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258122-B2 3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives ALMIRALL, S.A. (ES) 2012-09-04 US disclosed
US-8258122-B2 3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives ALMIRALL, S.A. (ES) 2012-09-04 US disclosed
US-8258122-B2 3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives ALMIRALL, S.A. (ES) 2012-09-04 US disclosed
US-20100120731-A1 3-([1,2,4]TRIAZOLO [4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES ALMIRALL, S.A. (ES) 2010-05-13 US disclosed
US-20100120731-A1 3-([1,2,4]TRIAZOLO [4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES ALMIRALL, S.A. (ES) 2010-05-13 US disclosed
US-20100120731-A1 3-([1,2,4]TRIAZOLO [4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES ALMIRALL, S.A. (ES) 2010-05-13 US disclosed
EP-2118100-A1 NEW 3- ([1,2,4] TRIAZOLO [4,3-A] PYRIDIN-7-YL)BENZAMIDE DERIVATIVES Almirall, S.A. (ES) 2009-11-18 EP disclosed
WO-2008107125-A1 NEW 3-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES ALMIRALL, S.A. (ES) 2008-09-12 WO disclosed
WO-2008107125-A1 NEW 3-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES ALMIRALL, S.A. (ES) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120731-A1 3-([1,2,4]TRIAZOLO [4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES MAP4K2, MAP3K7, MAPK7 LMNA 1448/4885SMN1; SMN2 2400/4885ALDH1A1 1882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.